This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
International Society for Pharmacoeconomics and Outcomes Research
2019 US dollars
Williamson T, et al. Economic Analysis of Inpatient Adverse Event-Related Expenditures in Metastatic Solid Tumor Patients Exposed to Larotrectinib or Entrectinib. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/98929
About this article
Cite this article
SAE-related costs lower with larotrectinib than with entrectinib. PharmacoEcon Outcomes News 855, 27 (2020). https://doi.org/10.1007/s40274-020-6892-4